HGSOC, endometrioid ovarian cancer, or ovarian clear cell carcinoma; no previous AKT or PI3K pathway or mTOR inhibitors; disease recurrence between 1 and 6 months after last dose of first-line platinum-based therapy or progression or relapse within 6 months of last dose of platinum-based second- to fifth-line therapies; 1–5 prior chemotherapies. This evidence concerns the gene MTOR and ovarian endometrioid adenocarcinoma.